EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats

Mohammad Zafar Imam, Andy Kuo, Sussan Ghassabian, Yunxin Cai, Yajuan Qin, Tingyou Li, Maree T Smith

Pharmacological Reports · 2023

DOI: 10.1007/s43440-023-00446-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, 2023. Verfasst von Mohammad Zafar Imam und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia Campus, Brisbane, QLD, 4072, Australia. Hauptthemen laut MEDLINE: Constipation, Morphine, Receptors, Opioid, delta, Respiratory Insufficiency. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council Large Linkage Grant, National Natural Science Foundation of China, UQ Graduate School Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Strong opioid analgesics such as morphine alleviate moderate to severe acute nociceptive pain (e.g. post-surgical or post-trauma pain) as well as chronic cancer pain. However, they evoke many adverse effects and so there is an unmet need for opioid analgesics with improved tolerability. Recently, a prominent hypothesis has been that opioid-related adverse effects are mediated by β-arrestin2 recruitment at the µ-opioid (MOP) receptor and this stimulated research on discovery of G-protein biassed opioid analgesics. In other efforts, opioids with MOP agonist and δ-opioid (DOP) receptor antagonist profiles are promising for reducing side effects c.f. morphine. Herein, we report on the in vivo pharmacology of a novel opioid peptide (CYX-5) that is a G-protein biassed MOP receptor agonist, DOP receptor antagonist and kappa opioid (KOP) receptor agonist.

Methods

Male Sprague–Dawley received intracerebroventricular bolus doses of CYX-5 (3, 10, 20 nmol), morphine (100 nmol) or vehicle, and antinociception (tail flick) was assessed relative to constipation (charcoal meal and castor oil-induced diarrhoea tests) and respiratory depression (whole body plethysmography).

Results

CYX-5 evoked naloxone-sensitive, moderate antinociception, at the highest dose tested. Although CYX-5 did not inhibit gastrointestinal motility, it reduced stool output markedly in the castor oil-induced diarrhoea test. In contrast to morphine that evoked respiratory depression, CYX-5 increased tidal volume, thereby stimulating respiration.

Conclusion

Despite its lack of recruitment of β-arrestin2 at MOP, DOP and KOP receptors, CYX-5 evoked constipation, implicating a mechanism other than β-arrestin2 recruitment at MOP, DOP and KOP receptors, mediating constipation evoked by CYX-5 and potentially other opioid ligands.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConstipationMorphineReceptors, Opioid, deltaRespiratory InsufficiencyAnimalsMaleRatsAnalgesics, OpioidCastor OilDiarrheaGTP-Binding ProteinsNarcotic AntagonistsRats, Sprague-DawleyReceptors, Opioid, mu

Stichwörter der Autor:innen

CYX-5Castor oil-induced diarrhoeaCharcoal mealGastrointestinal motilityHypercapniaIntracerebroventricular (icv)Minute ventilationWarm water tail flick testWhole body plethysmography

Substanzen

Analgesics, OpioidCastor OilGTP-Binding ProteinsMorphineNarcotic AntagonistsReceptors, Opioid, deltaReceptors, Opioid, mu

Autor:innen und Institutionen

  • School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia Campus, Brisbane, QLD, 4072, Australia.
  • School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China.
  • School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China. l_tingyou@njmu.edu.au.
  • School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia Campus, Brisbane, QLD, 4072, Australia. maree.smith@uq.edu.au.

Förderung

  • Australian Research Council Large Linkage Grant
  • National Natural Science Foundation of China
  • UQ Graduate School Scholarship
  • Research Training Program Scholarship
  • Queensland Government Smart State Research Facilities Programme
  • Australian Government National Collaborative Research Infrastructure Strategy 9NCRIS) program
  • Therapeutic Innovation Australia

Zitieren

APA

Imam, M. Z., Kuo, A., Ghassabian, S., Cai, Y., Qin, Y., Li, T., & Smith, M. T. (2023). CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats. Pharmacological Reports. https://doi.org/10.1007/s43440-023-00446-8

Vancouver

Imam MZ, Kuo A, Ghassabian S, Cai Y, Qin Y, Li T, et al. CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats. Pharmacological Reports. 2023. doi:10.1007/s43440-023-00446-8

BibTeX
@article{Imam2023,
  author = {Imam, Mohammad Zafar and Kuo, Andy and Ghassabian, Sussan and Cai, Yunxin and Qin, Yajuan and Li, Tingyou and Smith, Maree T},
  title = {CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats},
  journal = {Pharmacological Reports},
  year = {2023},
  doi = {10.1007/s43440-023-00446-8}
}
Kostenlos starten →